Evidence map›Paper›PMID 33353557›Full record

ArticleJournal of ovarian research2020

Germline variation of Ribonuclease H2 genes in ovarian cancer patients.

Rahel Polaczek, Peter Schürmann, Lisa-Marie Speith, Robert Geffers, Matthias Dürst, Peter Hillemanns, Tjoung-Won Park-Simon, Clemens Liebrich, Thilo Dörk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rahel PolaczekDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
Peter SchürmannDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
Lisa-Marie SpeithDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
Robert GeffersGenome Analytics Unit, Helmholtz Institute for Infection Research, Braunschweig, Germany.
Matthias DürstDepartment of Gynaecology and Obstetrics, University Clinics Jena, Jena, Germany.
Peter HillemannsDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
Tjoung-Won Park-SimonDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.
Clemens LiebrichDepartment of Gynaecology and Obstetrics, Hospital Wolfsburg, Wolfsburg, Germany.
Thilo DörkDepartment of Gynaecology and Obstetrics, Gynaecology Research Unit (OE 6411), Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany. doerk.thilo@mh-hannover.de.ORCID http://orcid.org/0000-0002-9458-0282
Medizinische Hochschule Hannover · DEFraunhofer Project Centre Wolfsburg · DEHelmholtz Centre for Infection Research · DEJena University Hospital · DE

Funding

Deutsche Forschungsgemeinschaft Do 761/15-1
6 · The paper itself

Abstract

Epithelial ovarian carcinoma (EOC) is a genetically heterogeneous disease that is partly driven by molecular defects in mismatch repair (MMR) or homology-directed DNA repair (HDR). Ribonuclease H2 serves to remove mis-incorporated ribonucleotides from DNA which alleviates HDR mechanisms and guides the MMR machinery. Although Ribonuclease H2 has been implicated in cancer, the role of germline variants for ovarian cancer is unknown. In the present case-control study, we sequenced the coding and flanking untranslated regions of the RNASEH2A, RNASEH2B and RNASEH2C genes, encoding all three subunits of Ribonuclease H2, in a total of 602 German patients with EOC and of 940 healthy females from the same population. We identified one patient with a truncating variant in RNASEH2B, p.C44X, resulting in a premature stop codon. This patient had high-grade serous EOC with an 8 years survival after platinum/taxane-based therapy. Subsequent analysis of TCGA data similarly showed a significantly longer progression-free survival in ovarian cancer patients with low RNASEH2B or RNASEH2C expression levels. In conclusion, loss-of-function variants in Ribonuclease H2 genes are not common predisposing factors in ovarian cancer but the possibility that they modulate therapeutic platinum response deserves further investigation.

Indexed as

Germ-Line MutationCase-Control StudiesComputational BiologyFemaleHumansMiddle AgedOvarian NeoplasmsProgression-Free SurvivalRibonuclease HRibonuclease Hribonuclease HIIEpithelial ovarian carcinomaHomologous recombinationMMR deficiencyPlatinum resistanceRibonucleotide excision repairRNase H2

Identifiers

PMID33353557
PMCPMC7756920
OpenAlexW3113802735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.